Supplementary Data 1 from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer
Esther Sanfeliu, A. Prat(Cancer Clinic), Sandra Cobo(Breast Cancer Research Foundation), Marta Tapia(Hospital Clínico Universitario de Valencia), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Jesús Soberino(Hospital Quirónsalud Barcelona), E. Hernández-Illán, Anabel Martínez-Romero(Josep Carreras Leukaemia Research Institute), Joel S. Parker(University of North Carolina at Chapel Hill), Cristina Tebar(Hospital Clínico Universitario de Valencia), Laia Paré(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Kepa Amillano(Hospital Universitari Sant Joan de Reus), Santiago Escrivá-de-Romaní(Unknown), Patricia Villagrasa, Cristina Saura(Vall d'Hebron Hospital Universitari), Wesley Buckingham(Hospital Costa del Sol), Montserrat Muñoz-Mateu(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Joan Anton Puig‐Butille(Instituto de Salud Carlos III), Francisco Pardo, Javier Cortés, Olga Martinez-Sáez, Fara Brasó-Maristany, Blanca González-Farré, Mercedes Marín-Aguilera, Eva Ciruelos, Serafín Morales, Pedro Jares(Hospital Clínic de Barcelona), Raquel Gómez-Bravo, Juan Miguel Cejalvo(Universitat de València)
Cited by 0
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k